Focused On-demand Library for Deoxyribonuclease gamma

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q13609

UPID:
DNSL3_HUMAN

ALTERNATIVE NAMES:
DNase I homolog protein DHP2; Deoxyribonuclease I-like 3; Liver and spleen DNase

ALTERNATIVE UPACC:
Q13609; B2R8B1; B7Z707; O75803

BACKGROUND:
The protein Deoxyribonuclease gamma, with alternative names DNase I homolog protein DHP2, Deoxyribonuclease I-like 3, and Liver and spleen DNase, is pivotal in DNA fragmentation during apoptosis and necrosis. It ensures the suppression of anti-DNA autoimmunity by acting on chromatin in apoptotic cell-derived microparticles and plays a key role with DNASE1 in the degradation of neutrophil extracellular traps (NETs), crucial for preventing clot formation and subsequent organ damage in inflammatory conditions.

THERAPEUTIC SIGNIFICANCE:
Deoxyribonuclease gamma's critical function in Systemic lupus erythematosus 16, marked by severe autoimmune responses and kidney involvement, underscores its potential as a therapeutic target. Exploring its mechanisms could unlock new pathways for treating systemic lupus erythematosus and other autoimmune disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.